Update on the management of gonorrhea in adults in the United States

Clinical Infectious Diseases

Volumn 44, Issue SUPPL. 3, 2007, Pages

  Newman, Lori M ^a,d   Moran, John S ^b   Workowski, Kimberly A ^a,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c EMORY UNIVERSITY   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFDINIR; CEFDITOREN; CEFIXIME; CEFODIZIME; CEFOTAXIME; CEFOXITIN; CEFPODOXIME PROXETIL; CEFTIBUTEN; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME AXETIL; CHLORHEXIDINE; CIPROFLOXACIN; ERTAPENEM; FROPENEM; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; NORFLOXACIN; OCIMUM SANCTUM EXTRACT; OFLOXACIN; PLANT EXTRACT; PROBENECID; SPECTINOMYCIN; TERMINALIA MACROPTERA EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; ANTIBIOTIC RESISTANCE; BACTERIUM CULTURE; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; GONORRHEA; HUMAN; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; UNITED STATES;

ADULT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; FEMALE; GONORRHEA; HUMANS; MALE; NEISSERIA GONORRHOEAE; QUINOLONES; UNITED STATES;

EID: 33947407633     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/511422     Document Type: Review

References (179)

1. Hook EW III, Handsfield HH. Gonococcal infections in the adult. In: Holmes KK, Sparling PF, Mardh P, et al., eds. Sexually transmitted diseases. 3rd ed. New York: McGraw-Hill, 1999:451-66.
2. Cohen MS. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1997; 349:1868-73.
3. Jajosky R. Summary of notifiable diseases-United States, 2004. MMWR Morb Mortal Wkly Rep 2006; 53:1-79.
4. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2004. Atlanta: US Department of Health and Human Services, 2005.
5. Datta SD, Sternberg M, Johnson RE, et al. Prevalence of chlamydia and gonorrhea in the United States among persons aged 14-39 years, 1999-2000 [abstract 0349]. In: Program and abstracts of the 2003 International Society for Sexually Transmitted Disease Research Congress (Ottawa). International Society for Sexually Transmitted Disease Research, 2003:122.
6. Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004; 291:2229-36.
7. Eng TR, Butler WT (eds). The hidden epidemic: confronting sexually transmitted diseases. Washington, DC: National Academy Press, 1997.
8. Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55(RR-11):1-94.
9. Tapsall J. Antimicrobial resistance in Neisseria gonorrhoeae. Geneva, Switzerland: World Health Organization, 2001.
10. Guidelines for the management of sexually transmitted infections. Geneva, Switzerland: World Health Organization, 2003.
11. Handsfield HH, McCutchan JA, Corey L, Ronald AR. Evaluation of new anti-infective drugs for the treatment of uncomplicated gonorrhea in adults and adolescents. Clin Infect Dis 1992; 15(Suppl 1): S123-30.
12. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20(Suppl 1): S47-65.
13. Jaffe HW. Pharmacokinetic determinants of penicillin cure of gonococcal urethritis. Antimicrob Agents Chemother 1979; 15:587-91.
14. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2002. MMWR Recomm Rep 2002; 51(RR-6):1-78.
15. Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men-United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR Morb Mortal Wkly Rep 2004; 53: 335-8.
16. Centers for Disease Control and Prevention. Notice to readers: discontinuation of cefixime tablets - United States. MMWR Morb Mortal Wkly Rep 2002; 51:1052.
17. Centers for Disease Control and Prevention. Antibiotic-resistant strains of Neisseria gonorrhoeae: policy guidelines for detection, management, and control. MMWR Morb Mortal Wkly Rep 1987; 36(Suppl 5):1S-18S.
18. Dicker L, Mosure DJ, Steece R, Stone K. Testing for sexually transmitted diseases in U.S. public health laboratories in 2004. Sex Trans Dis 2007; 34:41-6.
19. Roy K. Optimizing treatment of antimicrobial-resistant Neisseria gonorrhoeae. Emerg Infect Dis 2005; 11:1265-73.
20. Public Health Agency of Canada. Interim statement on the treatment of gonorrhea in Canada. Available at: http://www.phac-aspc.gc.ca/ std-mts/is-gonorrhea-2004_e.html. Accessed 11 April 2005.
21. Sarwal S, Wong T, Sevigny C, Ng LK. Increasing incidence of ciprofloxacin-resistant Neisseria gonorrhoeae infection in Canada. Canadian Medical Association Journal 2003; 168:872-3.
22. Newman LM, Wang SA, Ohye RG, O'Connor N, Lee MV, Weinstock HS. The epidemiology of fluoroquinolone-resistant Neisseria gonorrhoeae in Hawaii, 2001. Clin Infect Dis 2004; 38:649-54.
23. Macomber K. Drug-resistant Neisseria gonorrhoeae in Michigan. Emerg Infect Dis 2005; 11:1009-15.
24. Centers for Disease Control and Prevention (CDC). Gonococcal Isolate Surveillance Project (GISP) annual report - 2004. Atlanta: CDC, 2005.
25. Fiorito S, Galarza P, Pagano I, et al. Emergence of high level ciprofloxacin resistant Neisseria gonorrhoeae strain in Buenos Aires, Argentina. Sex Transm Infect 2001; 77:77.
26. Famiglietti A, Garcia SD, de Mier CA, et al. Evolution of Neisseria gonorrhoeae drug susceptibility in Buenos Aires, Argentina, 1985-99. Sex Transm Infect 2001; 77:142.
27. Dillon JA, Rubabaza JP, Benzaken AS, et al. Reduced susceptibility to azithromycin and high percentages of penicillin and tetracycline resistance in Neisseria gonorrhoeae isolates from Manaus, Brazil, 1998. Sex Transm Dis 2001; 28:521-6.
28. Llanes R, Sosa J, Guzman D, et al. Antimicrobial susceptibility of Neisseria gonorrhoeae in Cuba (1995-1999): implications for treatment of gonorrhea. Sex Transm Dis 2003; 30:10-4.
29. Castor D, Prabhakar P, Furlonge C, et al. Antibiotic resistant N. gonorrhoeae in Trinidad and Tobago. Cell Mol Biol 2001; 47:987-95.
30. Dillon JA, Li H, Sealy J, Ruben M, Prabhakar P, Caribbean GASP Network. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from three Caribbean countries: Trinidad, Guyana, and St. Vincent. Sex Transm Dis 2001; 28:508-14.
31. Dillon JA. Challenges in the control of gonorrhea in South America and the Caribbean: monitoring the development of resistance to antibiotics. Sex Transm Dis 2006; 33:87-95.
32. Uthman AP, Heller-Vitouch CM, Stary AM, et al. High-frequency of quinolone-resistant Neisseria gonorrhoeae in Austria with a common pattern of triple mutations in GyrA and ParC genes. Sex Transm Dis 2004; 31:616-8.
33. Su X, Lind I. Molecular basis of high-level ciprofloxacin resistance in Neisseria gonorrhoeae strains isolated in Denmark from 1995 to 1998. Antimicrob Agents Chemother 2001; 45:117-23.
34. GRASP Steering Group. The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) year 2004 report. London: Health Protection Agency, 2005.
35. Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG. Changing epidemiologic profile of quinolone-resistant Neisseria gonorrhoeae in London. J Infect Dis 2005; 192:1191-5.
36. Nissinen A, Huovinen P. FiRe works - the Finnish Study Group for Antimicrobial Resistance (FiRe). Available at: http://www .eurosurveillance.org/ em/v05n12/0512-222.asp. Accessed 7 February 2005.
37. Herida M. Increase of Neisseria gonorrhoeae ciprofloxacin resistance in France in 2001-2003. Sex Transm Dis 2006; 33:6-7.
38. Enders M. Antimicrobial resistance of Neisseria gonorrhoeae isolates from the Stuttgart and Heidelberg areas of southern Germany. Eur J Clin Microbiol Infect Dis 2006; 25:318-22.
39. Dragsted D, Poulsen P, Norgaard C, Lind I. Antimicrobial susceptibility of Neisseria gonorrhoeae strains isolated in Nuuk, Greenland during 1998-1999. Int J STD AIDS 2002; 13:826-8.
40. Hopkins S. Increasing resistance to ciprofloxacin among isolates of Neisseria gonorrhoea in Dublin. Ir Med J 2005; 98:208-9.
41. Kolader M, Peerbooms PG, Vader PC, van Bergen JE, Fennema JS, de Vries HJ. The rise in fluoroquinolone-resistant Neisseria gonorrhoeae among people attending the Municipal Health Service's clinic for sexually transmitted diseases in Amsterdam, the Netherlands; cefotaxime now first-choice treatment for uncomplicated gonorrhoea. Ned Tijdschr Geneeskd 2004; 148:2129-32.
42. Borgen K. Increase of gonococcal quinolone resistance in the Netherlands from 2002-2004. Euro Surveill 2005; 10:E051117.
43. Forsyth A, Moyes A, Young H. Increased ciprofloxacin resistance in gonococci isolated in Scotland. Lancet 2000; 356:1984-5.
44. Berglund T, Colucci B, Lund B, Qvarnstrom I, Sandstrom E. Increasing incidence of ciprofloxacin resistant gonorrhea in Sweden: choose a correct antibiotic and follow up the treatment! [in Swedish]. Lakartidningen 2004; 101:2332-5.
45. Berglund T, Unemo M, Olcen P, Giesecke J, Fredlund H. One year of Neisseria gonorrhoeae isolates in Sweden: the prevalence study of antibiotic susceptibility shows relation to the geographic area of exposure. Int J STD AIDS 2002; 13:109-14.
46. Arreaza L, Salcedo C, Alcala B, Berron S, Martin E, Vazquez JA. Antibiotic resistance of Neisseria gonorrhoeae in Spain: trends over the last two decades. J Antimicrob Chemother 2003; 51:153-6.
47. Aydin D, Kucukbasmaci O, Gonullu N, Aktas Z. Susceptibilities of Neisseria gonorrhoeae and Ureaplasma urealyticum isolates from male patients with urethritis to several antibiotics including telithromycin. Chemotherapy 2005; 51:89-92.
48. Van Dyck E, Alary M, Guedou A, Abdellati S, Lafia E, Anagonou S. Antimicrobial susceptibilities and plasmid patterns of Neisseria gonorrhoeae in Benin. Int J STD AIDS 2001; 12:89-93.
49. Alami K, Ait MN, Akrim M, et al. Urethral discharge in Morocco: prevalence of microorganisms and susceptibility of gonococcus. East Mediterr Health J 2002; 8:794-804.
50. Dan M, Poch F, Sheinberg B. High prevalence of high-level ciprofloxacin resistance in Neisseria gonorrhoeae in Tel Aviv, Israel: correlation with response to therapy. Antimicrob Agents Chemother 2002; 46:1671-3.
51. Yagupsky P, Schahar A, Peled N, et al. Increasing incidence of gonorrhea in Israel associated with countrywide dissemination of a ciprofloxacin-resistant strain. Eur J Clin Microbiol Infect Dis 2002; 21: 368-72.
52. Sharma AK. Antimicrobial sensitivity of Neisseria gonorrhoeae: a hospital-based study from Kuwait. J Chemother 2005; 17:117-8.
53. Van Dyck E, Karita E, Abdellati S, et al. Antimicrobial susceptibilities of Neisseria gonorrhoeae in Kigali, Rwanda, and trends of resistance between 1986 and 2000. Sex Transm Dis 2001; 28:539-45.
54. Balkhy HH, Memish ZA, Rich M. Antibiotic susceptibility of Neisseria gonorrhoeae in Riyadh, Saudi Arabia. J Chemother 2003; 15:95-6.
55. Moodley P. Ciprofloxacin-resistant gonorrhoea in South Africa. Lancet 2005; 366:1159.
56. Australian Gonococcal Surveillance Programme. Annual report of the Australian Gonococcal Surveillance Programme, 2005. Commun Dis Intell 2006; 30:205-10.
57. Veitch MG, Griffith JM, Morgan ML. Ciprofloxacin resistance emerges in Neisseria gonorrhoeae in Victoria, 1998 to 2001. Commun Dis Intell 2003; 27(Suppl):S75-9.
58. ICDDR,B Centre for Health and Population Research. Surveillance update - Bangladesh. Available at: http://www.icddrb.org/ pub/publication.jsp? classificationID=0&pubID=4677. Accessed 15 February 2005.
59. Fei S, Luo Q, Cao W, Zhang X. Resistance of Neisseria gonorrhoeae to 4 antibiotics: an analysis of the situation in Guangzhou in 2002. Di Yi Jun Yi Da Xue Xue Bao 2003; 23:1099-100.
60. Bala M, Ray K, Kumari S. Alarming increase in ciprofloxacin- and penicillin-resistant Neisseria gonorrhoeae isolates in New Delhi, India. Sex Transm Dis 2003; 30:523-5.
61. Ieven M, Van Looveren M, Sudigdoadi S, et al. Antimicrobial susceptibilities of Neisseria gonorrhoeae strains isolated in Java, Indonesia. Sex Transm Dis 2003; 30:25-9.
62. Donegan E, Wirawan D, Muliawan P, et al. Fluoroquinolone-resistant Neisseria gonorrhoeae in Bali, Indonesia: 2004. Sex Transm Dis 2006; 33:625-9.
63. Ito M, Yasuda M, Yokoi S, et al. Remarkable increase in central Japan in 2001-2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones. Antimicrob Agents Chemother 2004; 48:3185-7.
64. Dorlencourt F, Boireaux C, Sednaoui P, Danilenko NV, Legros D. In vitro susceptibility of 120 strains of Neisseria gonorrhoeae isolated in Kyrghyzstan. Sex Transm Dis 2002; 29:376-8.
65. Lkhamsuren E, Shultz TR, Limnios EA, Tapsall JW. The antibiotic susceptibility of Neisseria gonorrhoeae isolated in Ulaanbaatar, Mongolia. Sex Transm Infect 2001; 77:218-9.
66. Chaudhary C. A pilot study on antimicrobial susceptibility of Neisseria gonorrhoeae isolates from Nepal. Sex Transm Dis 2005; 32:641-3.
67. Heffernan H, Brokenshire M, Woodhouse R, MacCarthy A, Blackmore T. Antimicrobial susceptibility among Neisseria gonorrhoeae in New Zealand in 2002. N Z Med J 2004; 117:U817.
68. Jabeen K. Emergence of quinolone-resistant Neisseria gonorrhoeae in Pakistan. Int J STD AIDS 2006; 17:30-3.
69. Aplasca De Los Reyes MR, Pato-Mesola V, Klausner JD, et al. A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines. Clin Infect Dis 2001; 32:1313-8.
70. Hsueh PR, Tseng SP, Teng LJ, Ho SW High prevalence of ciprofloxacin-resistant Neisseria gonorrhoeae in Northern Taiwan. Clin Infect Dis 2005; 40:188-92.
71. Trees DL, Sirivongrangson P, Schultz AJ, et al. Multiclonal increase in ciprofloxacin-resistant Neisseria gonorrhoeae, Thailand, 1998-1999. Sex Transm Dis 2002; 29:668-73.
72. World Health Organization Western Pacific Gonococcal Antimicrobial Surveillance Programme. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2004. Commun Dis Intell 2006; 30:129-32.
73. Ray K. Antimicrobial resistance of Neisseria gonorrhoeae in selected World Health Organization Southeast Asia Region countries: an overview. Sex Transm Dis 2005; 32:178-84.
74. Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae-Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep 2002; 51:1041-41.
75. Centers for Disease Control and Prevention. Fluoroquinolone-resistance in Neisseria gonorrhoeae, Hawaii, 1999, and decreased susceptibility to azithromycin in N. gonorrhoeae, Missouri, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:833-7.
76. Centers for Disease Control and Prevention. Gonococcal Isolate Surveillance Project. Available at: http://www.cdc.gov/std/GISP. Accessed 8 January 2007.
77. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006. Available at: http://www.cdc.gov/std/ treatment. Accessed 8 January 2007.
78. Moran JS, Handsfield HH. Neisseria gonorrhoeae. In: Yu VL, Weber R, Raoult D, eds. Antimicrobial therapy and vaccines. 2nd ed. New York: Apple Trees Productions, 2002:457-69.
79. Centers for Disease Control and Prevention. Oral alternatives to cefixime for the treatment of uncomplicated Neisseria gonorrhoeae urogenital infections. Available at: http://www.cdc.gov/STD/treatment/cefixime.htm. Accessed 3 November 2004.
80. Ramus RM, Sheffield JS, Mayfield JA, Wendel GD Jr. A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy. Am J Obstet Gynecol 2001; 185:629-32.
81. Waugh MA. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women. J Antimicrob Chemother 1993; 31(Suppl E): 193-8.
82. Lassus A. Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. J Antimicrob Chemother 1990; 25(Suppl A):115-21.
83. Habib AR, Fernando R. Efficacy of azithromycin 1g single dose in the management of uncomplicated gonorrhoea. Int J STD AIDS 2004; 15:240-2.
84. Swanston WH, Prabhakar P, Barrow L, Mahabir BS, Furlonge C. Single dose (direct observed) azithromycin therapy for Neisseria gonorrhoeae and Chlamydia trachomatis in STD clinic attenders with genital discharge in Trinidad and Tobago. West Indian Med J 2001; 50:198-202.
85. Handsfield HH. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Sex Transm Dis 1994; 21:107-11.
86. Deguchi T, Yasuda M, Yokoi S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003; 9:35-9.
87. Portilla I, Lutz B, Montalvo M, Mogabgab WJ. Oral cefixime versus intramuscular ceftriaxone in patients with uncomplicated gonococcal infections. Sex Transm Dis 1992; 19:94-8.
88. Handsfield HH, McCormack WM, Hook EW III, et al. A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. N Engl J Med 1991; 325:1337-41.
89. Plourde PJ, Tyndall M, Agoki E, et al. Single-dose cefixime versus single-dose ceftriaxone in the treatment of antimicrobial-resistant Neisseria gonorrhoeae infection. J Infect Dis 1992; 166:919-22.
90. Kuhlwein A, Nies BA. Efficacy and safety of a single 400 mg oral dose of cefixime in the treatment of uncomplicated gonorrhea. Eur J Clin Microbiol Infect Dis 1989; 8:261-2.
91. Megran DW, Lefebvre K, Willetts V, Bowie WR. Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men. Antimicrob Agents Chemother 1990; 34:355-7.
92. Das RP, Jones K, Robinson AJ, Timmins DJ. Cefuroxime axetil to treat gonorrhea. Genitourin Med 1988; 64:394.
93. Novak E, Paxton LM, Tubbs HJ, Turner LF, Keck CW, Yatsu J. Orally administered cefpodoxime proxetil for treatment of uncomplicated gonococcal urethritis in males: a dose-response study. Antimicrob Agents Chemother 1992; 36:1764-5.
94. Chong LY, Cheung WM, Leung CS, Yu CW, Chan LY. Clinical evaluation of ceftibuten in gonorrhea: a pilot study in Hong Kong. Sex Transm Dis 1998; 25:464-7.
95. Gottlieb A, Mills J. Cefuroxime axetil for treatment of uncomplicated gonorrhea. Antimicrob Agents Chemother 1986; 30:333-4.
96. Kinghorn GR, Spencer RC, Smith TK, Woolley PD, Patel R, Robinson AJ. Comparative study of cefuroxime axetil and procaine penicillin in the treatment of uncomplicated gonorrhoea. Int J STD AIDS 1990; 1:285-7.
97. Reichman RC, Nolte FS, Wolinsky SM, Greisberger CA, Trupei MA, Nitzkin J. Single-dose cefuroxime axetil in the treatment of uncomplicated gonorrhea: a controlled trial. Sex Transm Dis 1985; 12:184-7.
98. Thorpe EM, Schwebke JR, Hook EW III, et al. Comparison of single-dose cefuroxime axetil with ciprofloxacin in treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing Neisseria gonorrhoeae strains. Antimicrob Agents Chemother 1996; 40:2775-80.
99. Ison CA, Mouton JW, Jones K, Fenton KA, Livermore DM. Which cephalosporin for gonorrhoea? Sex Transm Infect 2004; 80:386-8.
100. Muratani T, Akasaka S, Kobayashi T, et al. Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrob Agents Chemother 2001; 45:3603-6.
101. Akasaka S, Muratani T, Yamada Y, Inatomi H, Takahashi K, Matsumoto T. Emergence of cephem- and aztreonam-high-resistant Neisseria gonorrhoeae that does not produce β-lactamase. J Infect Chemother 2001; 7:49-50.
102. Tanaka M, Nakayama H, Tunoe H, et al. A remarkable reduction in the susceptibility of Neisseria gonorrhoeae isolates to cephems and the selection of antibiotic regimens for the single-dose treatment of gonococcal infection in Japan. J Infect Chemother 2002; 8:81-6.
103. Muratani T, Kobayashi T, Oshi M, et al. The susceptibility of gonococcal isolates to penicillins, cephems, quinolones, tetracyclines, and spectinomycin in various areas of Japan in 2002 [abstract 0375]. In: Program and abstracts of the 2003 International Society for Sexually Transmitted Disease Research Congress (Ottawa). International Society for Sexually Transmitted Disease Research, 2003:132.
104. Takahashi K, Muratani T, Kobayashi T, Yamada Y, Inatomi H, Matsumoto T. Emergence and prevalence of multi-drug resistant Neisseria gonorrhoeae (fluoroquinolones, tetracyclines, penicillins, 1st and 2nd generation cephems, and oral 3rd generation cephems) in Japan [abstract 882]. In: Program and abstracts of the 2001 Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
105. Hoffmann SH, Lambertsen L, Berthelsen L, Cowan S. Neisseria gonorrhoeae with increasing ceftriaxone MIC in Denmark in 2004: serotyping, bi-locus sequence typing, and sexual preference [abstract WP-035]. In: Program and abstracts of the 2005 International Society for Sexually Transmitted Disease Research Congress (Amsterdam). International Society for Sexually Transmitted Disease Research, 2005: 249.
106. WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2004. Commun Dis Intell 2006; 30:129-32.
107. Wang SA, Lee MV, O'Connor N, et al. Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime - Hawaii, 2001. Clin Infect Dis 2003; 37:849-52.
108. Tanaka M. Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone susceptibility that shows a multidrug-resistant phenotype. Int J Antimicrob Agents 2006; 27:20-6.
109. Centers for Disease Control and Prevention. Notice to readers: discontinuation of spectinomycin. MMWR Morb Mortal Wkly Rep 2006; 55:370.
110. Maness MJ. Ribosomal resistance to streptomycin and spectinomycin in Neisseria gonorrhoeae. J Bacteriol 1974; 120:1293-9.
111. McCormack WM. Drugs five years later: spectinomycin. Ann Intern Med 1976; 84:712-6.
112. Boslego JW. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987; 317:272-8.
113. Ehret JM. A clinical isolate of Neisseria gonorrhoeae with in vitro resistance to erythromycin and decreased susceptibility to azithromycin. Sex Transm Dis 1996; 23:270-2.
114. Young H. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS 1997; 8: 299-302.
115. Johnson SR, Sandul AL, Parekh M, Wang SA, Knapp JS, Trees DL. Mutations causing in vitro resistance to azithromycin in Neisseria gonorrhoeae. Int J Antimicrob Agents 2003; 21:414-9.
116. Xia M, Whittington WL, Shafer WM, Holmes KK. Gonorrhea among men who have sex with men: outbreak caused by a single genotype of erythromycin-resistant Neisseria gonorrhoeae with a single-base pair deletion in the mtrR promoter region. J Infect Dis 2000; 181:2080-2.
117. Rouquette-Loughlin CC. Characterization of the MacA-MacB efflux system in Neisseria gonorrhoeae. J Antimicrob Chemother 2005; 56: 856-60.
118. Zarantonelli L. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. Antimicrob Agents Chemother 1999; 43:2468-72.
119. Hagman KE, Pan W, Spratt BG, Balthazar JT, Judd RC, Shafer WM. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology 1995; 141:611-22.
120. Tapsall JW. Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters. Sex Transm Dis 1998; 25: 505-8.
121. McLean CA, Wang SA, Hoff GL, et al. The emergence of Neisseria gonorrhoeae with decreased susceptibility to azithromycin in Kansas City, Missouri, 1999 to 2000. Sex Transm Dis 2004; 31:73-8.
122. Tapsall J. Current concepts in the management of gonorrhoea. Expert Opin Pharmacother 2002; 3:147-57.
123. Waters LJ. Efficacy of azithromycin 1 g single dose in the management of uncomplicated gonorrhoea. Int J STD AIDS 2005; 16:84.
124. US Food and Drug Administration. Drugs@FDA. Available at: http: //www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed 8 January 2007.
125. Stoner BP, Douglas JM Jr, Martin DH, et al. Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea: a randomized, double-blind, multicenter trial. Sex Transm Dis 2001; 28:136-42.
126. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Tweedy KG. Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. JAMA 2002; 287:1117-22.
127. Matsumoto T, Muratani T, Takahashi K, et al. Single dose of cefodizime completely eradicated multidrug-resistant strain of Neisseria gonorrhoeae in urethritis and uterine cervicitis. J Infect Chemother 2006; 12:97-9.
128. Rabe LK, Hillier SL. Effect of chlorhexidine on genital microflora, Neisseria gonorrhoeae, and Trichomonas vaginalis in vitro. Sex Transm Dis 2000; 27:74-8.
129. Livermore DM, Alexander S, Marsden B, et al. Activity of ertapenem against Neisseria gonorrhoeae. J Antimicrob Chemother 2004; 54: 280-1.
130. Jones RN. Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains. Diagn Microbiol Infect Dis 2005; 53:311-7.
131. Deshpande L, Biedenbach DJ, Jones RN. Antimicrobial activity of BMS 284756 (T-3811) against Neisseria gonorrhoeae tested by three methods. Int J Antimicrob Agents 2001; 18:437-40.
132. Jones RN, Deshpande LM, Erwin ME, Barrett MS, Beach ML. Antigonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods. J Antimicrob Chemother 2000; 45(Suppl 1):67-70.
133. Ruiz J, Marco F, Sierra JM, et al. In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene. Int J Antimicrob Agents 2003; 22:73-6.
134. Tanaka M, Tunoe H, Mochida O, et al. Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates. Diagn Microbiol Infect Dis 2000; 38:109-13.
135. Berron S, Vazquez JA, Gimenez MJ, de la Fuente L, Aguilar L. In vitro susceptibilities of 400 Spanish isolates of Neisseria gonorrhoeae to gemifloxacin and 11 other antimicrobial agents. Antimicrob Agents Chemother 2000; 44:2543-4.
136. Pottumarthy S, Fritsche TR, Jones RN. Activity of gemifloxacin tested against Neisseria gonorrhoeae isolates including antimicrobial-resistant phenotypes. Diagn Microbiol Infect Dis 2006; 54:127-34.
137. Jones RN. Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria gonorrhoeae and Neisseria meningitidis. Diagn Microbiol Infect Dis 2005; 51:139-41.
138. Shokeen P. Preliminary studies on activity of Ocimum sanctum, Drynaria quercifolia, and Annona squamosa against Neisseria gonorrhoeae. Sex Transm Dis 2005; 32:106-11.
139. Bozja J. Porphyrin-based compounds exert antibacterial action against the sexually transmitted pathogens Neisseria gonorrhoeae and Haemophilus ducreyi. Int J Antimicrob Agents 2004; 24:578-84.
140. Tanaka M, Nakayama H, Haraoka M, Saika T, Kobayashi I, Naito S. Susceptibilities of Neisseria gonorrhoeae isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics. Antimicrob Agents Chemother 2000; 44:192-5.
141. Muratani T. In vitro antibacterial activities of telithromycin against clinical isolates of Neisseria gonorrhoeae. Jpn J Antibiot 2005; 58: 317-25.
142. Silva O, Ferreira E, Vaz PM, Canica M, Gomes ET. In vitro anti-Neisseria gonorrhoeae activity of Terminalia macroptera leaves. FEMS Microbiol Lett 2002; 217:271-4.
143. Deshpande LM, Gales AC, Jones RN. GAR-936 (9-t-butylglycylamido- minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria. Int J Antimicrob Agents 2001; 18:29-35.
144. Spencer SE, Valentin-Bon IE, Whaley K, Jerse AE. Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model. J Infect Dis 2004; 189:410-9.
145. Cavenee MR. Treatment of gonorrhea in pregnancy. Obstet Gynecol 1993; 81:33-8.
146. Brocklehurst P. Antibiotics for gonorrhoea in pregnancy. Cochrane Database Syst Rev 2002; (2):CD000098.
147. Hollier LM. Treatment of sexually transmitted infections in pregnancy. Clin Perinatol 2005; 32:629-56.
148. Moran J. Gonorrhoea. Clin Evid 2005;(13):2016-23.
149. Burstein GR, Berman SM, Blumer JL, Moran JS. Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: does the benefit outweigh the risk? Clin Infect Dis 2002; 35(Suppl 2): S191-9.
150. Collis TK. The clinical manifestations and treatment of sexually transmitted diseases in human immunodeficiency virus-positive men. Clin Infect Dis 2001; 32:611-22.
151. Bro-Jorgensen A. Gonococcal pharyngeal infections: report of 110 cases. Br J Vener Dis 1973; 49:491-9.
152. Tice AW. Pharyngeal gonorrhea. JAMA 1981; 246:2717-9.
153. Wiesner PJ, Tronca E, Bonin P, Pedersen AH, Holmes KK. Clinical spectrum of pharyngeal gonococcal infection. N Engl J Med 1973; 288:181-5.
154. Goldstone SE, Zatezalo C. High rates of sexually transmitted infections among men who have sex with men as seen in a surgical practice [abstract 922]. In: Program and abstracts of the 434th Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2005:203.
155. Janier M. Pharyngeal gonorrhoea: the forgotten reservoir. Sex Transm Infect 2003; 79:345.
156. Page-Shafer K. Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhea in men who have sex with men. Clin Infect Dis 2002; 34:173-6.
157. Lister NA. Testing men who have sex with men for Neisseria gonorrhoeae and Chlamydia trachomatis prior to the introduction of guidelines at an STD clinic in Melbourne. Sexual Health 2004; 1: 47-50.
158. Phipps W. Syphilis, chlamydia, and gonorrhea screening in HIV-infected patients in primary care, San Francisco, California, 2003. AIDS Patient Care STDS 2005; 19:495-8.
159. Lafferty WE. Sexually transmitted diseases in men who have sex with men: acquisition of gonorrhea and nongonococcal urethritis by fellatio and implications for STD/HIV prevention. Sex Transm Dis 1997; 24:272-8.
160. Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis 1995; 22: 39-47.
161. Dan M, Poch F, Amitai Z, Gefen D, Shohat T. Pharyngeal gonorrhea in female sex workers: response to a single 2-g dose of azithromycin. Sex Transm Dis 2006; 33:512-5.
162. Lentz JW. Gonorrhea repeater demonstration project; preliminary report from Philadelphia. Am J Syph Gonorrhea Vener Dis 1953; 37: 577-87.
163. Oh MK, Cloud GA, Fleenor M, Sturdevant MS, Nesmith JD, Feinstein RA. Risk for gonococcal and chlamydial cervicitis in adolescent females: incidence and recurrence in a prospective cohort study. J Adolesc Health 1996; 18:270-5.
164. Thomas JC, Weiner DH, Schoenbach VJ, Earp JA. Frequent re-infection in a community with hyperendemic gonorrhoea and chlamydia: appropriate clinical actions. Int J STD AIDS 2000; 11:461-7.
165. Burstein GR, Gaydos CA, Diener-West M, Howell MR, Zenilman JM, Quinn TC. Incident Chlamydia trachomatis infections among innercity adolescent females. Sex Transm Infect 2001; 77:26-32.
166. Chamot E, Coughlin SS, Farley TA, Rice JC. Gonorrhea incidence and HIV testing and counseling among adolescents and young adults seen at a clinic for sexually transmitted diseases. AIDS 1999; 13:971-9.
167. Ellen JM, Hessol NA, Kohn RP, Bolan GA. An investigation of geographic clustering of repeat cases of gonorrhea and chlamydial infection in San Francisco, 1989-1993: evidence for core groups. J Infect Dis 1997; 175:1519-22.
168. Fortenberry JD, Brizendine EJ, Katz BP, Wools KK, Blythe MJ, Orr DP. Subsequent sexually transmitted infections among adolescent women with genital infection due to Chlamydia trachomatis, Neisseria gonorrhoeae, or Trichomonas vaginalis. Sex Transm Dis 1999; 26:26-32.
169. Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676-85.
170. Gunn RA, Maroufi A, Fox KK, Berman SM. Surveillance for repeat gonorrhea infection, San Diego, California, 1995-2001: establishing definitions and methods. Sex Transm Dis 2004; 31:373-9.
171. Gunn RA, Fitzgerald S, Aral SO. Sexually transmitted disease clinic clients at risk for subsequent gonorrhea and chlamydia infections: possible 'core' transmitters. Sex Transm Dis 2000; 27:343-9.
172. Kissinger P. Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. Clin Infect Dis 2005; 41:623-9.
173. Orr DP. Subsequent sexually transmitted infection in urban adolescents and young adults. Arch Pediatr Adolesc Med 2001; 155:947-53.
174. Peterman TA, Tian L, Metcalf CA, Malotte CK, Paul SM, Douglas JM Jr. High incidence of new asymptomatic infection following treatment for chlamydia, gonorrhea, or trichomonas [abstract TP-159]. In: Program and abstracts of the
175. Fung M, Kent C, Klausner J. Chlamydia and gonorrhea re-infection of males: a systematic review of data to evaluate the need for retesting [abstract P29]. In: Program and abstracts of 2006 National STD Prevention Conference (Jacksonville). Atlanta: Centers for Disease Control and Prevention, 2006:151.
176. Newman L, Warner L, Weinstock H. Predicting subsequent infection in patients attending sexually transmitted disease clinics. Sex Transm Dis 2006; 33:737-42.
177. Hillis SD. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol 1997; 176(1 Pt 1):103-7.
178. Westrom LV. Sexually transmitted diseases and infertility. Sex Transm Dis 1994; 21(2 Suppl):S32-7.
179. Schillinger JA. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex Transm Dis 2003; 30:49-56.